German National Registry for NSS

Status Not yet recruiting

Clinical Trial Summary

The G-NeSS Registry prospectively collects data on clinical and outcome variables from patients undergoing partial nephrectomy for renal masses. Analyses of data aims at identifying key factors determining the quality of surgical care in this patient population.

Clinical Trial Description

Today the majority of patients with renal tumors is diagnosed with localized disease amenable to nephron-sparing surgery (NSS). Partial nephrectomy (PN) constitutes the reference standard treatment for small renal masses according to international guidelines. Open PN ist still the predominant apporach in Germany, but the use of minimally-invasive surgery has continously increased over the last decades. Specifically, robotic surgery is on the rise and may facilitate the adoption of a minimally-invasive PN approach even in more complex renal tumours. Real world data on the outcomes of PN according to the surgical approach are limited. Data from cancer registries and health insurance databases usually lack important information an key patient und tumour characteristics, such as tumour complexity. The G-NESS registry database aims at prospectively collecting such clinical and outcome data from patients undergoing PN. Data collection includes perioperative variables on patient characteristics, tumour location and complexity, surgical approach, intra-/postoperative complications, and kidney function. Follow-up based on questionnaires is conducted after predefined intervals (i.e. 30 days, 12 months, 24 months, and 60 months) in order to receive information on long-term kidney function, comorbidities, and survival. The information received from the database can help to better define the optimal surgical care for patients with renal masses. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04681690
Study type	Observational [Patient Registry]
Source	Association of Urologic Oncology (AUO)
Contact	Nina Harke, Dr.
Phone	0511/532
Email	harke.nina@mh-hannover.de
Status	Not yet recruiting
Phase
Start date	December 15, 2020
Completion date	September 15, 2027

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01961583` - [18F]Fluciclatide PET Imaging of Pazopanib Response	Phase 2
Completed	`NCT00001302` - A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833	Phase 1
Completed	`NCT01896778` - Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer	N/A
Enrolling by invitation	`NCT02287987` - CLamp vs Off Clamp Kidney During Partial Nephrectomy	N/A
Recruiting	`NCT04644432` - Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma	Phase 2
Active, not recruiting	`NCT05817604` - Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors (SABINA Trial)
Completed	`NCT00888641` - A Pilot Study of Renal Hypothermia During Partial Nephrectomy	Phase 1
Completed	`NCT00199875` - Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250	Phase 1
Recruiting	`NCT00994188` - A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Family Members	N/A
Recruiting	`NCT02346435` - The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry
Completed	`NCT01087060` - Detection of Renal Malignancy of Complicated Renal Cysts	N/A
Recruiting	`NCT04258462` - Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors	Phase 2
Recruiting	`NCT00898365` - Study of Kidney Tumors in Younger Patients
Recruiting	`NCT03996850` - SPECT/CT for the Characterization of Renal Masses
Recruiting	`NCT04823923` - Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer	N/A
Not yet recruiting	`NCT05135832` - Patient Reported Outcomes by Patients With Metastatic Renal Cell Carcinoma	N/A
Recruiting	`NCT04602702` - Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid Tumors
Terminated	`NCT00005655` - Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer	Phase 1
Recruiting	`NCT05887245` - Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy
Recruiting	`NCT06467097` - Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell Carcinoma	Phase 3